Drug details

Fiasp (insulin aspart injection for subcutaneous or intravenous use)

type of Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins

Fiasp (insulin aspart injection) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • nausea,
  • confusion,
  • tiredness,
  • stomach pain,
  • dizziness,
  • blurred vision,
  • dry mouth,
  • headache,
  • sweating,
  • increased urination,
  • fruity breath odor,
  • loss of consciousness
  • increased hunger or thirst,
  • anxiety,
  • feeling cold,
  • dry skin,
  • shakiness,
  • increased hunger,
  • unusually weakness,
  • irritable,
  • fast heartbeat, and
The following drugs are related to Fiasp, either as a replacement or used together:
  • Diabinese (chlorpropamide)
  • Zegalogue (dasiglucagon injection)
  • Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
  • Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets)
  • Glucotrol (glipizide)
  • Lyumjev (insulin lispro-aabc injection)
  • Invega (paliperidone)
  • Mounjaro (tirzepatide injection)
  • Starlix Tablet (nateglinide)
  • Prandin (repaglinide)
  • Tzield (teplizumab-mzwv injection, for intravenous use)